Halozyme Therapeutics: The License to Print Money: Why This Biotech Stock Is Not a Risky Bet

Halozyme operates not as a speculative drug developer, but as a highly profitable licensing company that occupies a monopoly-like niche for simplifying infusion therapies. Thanks to a high EBITDA margin of over 60%, the company generates reliable, robust cash flows. With new technologies for self-administration of medications at home and a well-filled partner pipeline, Halozyme sustainably benefits from the shift towards outpatient cancer therapies. Those investing in biotechnology on the stock market often need strong nerves. Many companies...